ALGS Stock Summary and Trading Ideas (Aligos Therapeutics | NASDAQ:ALGS)

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Aligos Therapeutics trades on the NASDAQ stock market under the symbol ALGS.

As of November 13, 2026, ALGS stock price climbed to $2.10 with 56,451 million shares trading.

ALGS has a beta of 0.79, meaning it tends to be less sensitive to market movements. ALGS has a correlation of 0.01 to the broad based SPY ETF.

ALGS has a market cap of $13.11 million. This is considered a Sub-Micro Cap stock.

Last quarter Aligos Therapeutics reported $3 million in Revenue and -$2.09 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.42.

In the last 3 years, ALGS traded as high as $46.80 and as low as $1.92.

The top ETF exchange traded funds that ALGS belongs to (by Net Assets): VTI, VXF, IWC, DFMC, DFAS.

ALGS has underperformed the market in the last year with a price return of -65.4% while the SPY ETF gained +13.4%. ALGS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -69.0% and -56.3%, respectively, while the SPY returned -2.8% and -0.2%, respectively.

ALGS support price is $1.81 and resistance is $2.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALGS shares will trade within this expected range on the day.